Studies on the new emerging Laccococcus garvieae serotype II infection and its vaccine development
| Project/Area Number |
15K07554
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Aquatic bioproduction science
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Fukuda Yutaka 大分県農林水産研究指導センター, 水産研究部
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | Lactococcus garvieae / serotype I / serotype II / vaccine / Seriola / emerging / pathogen / serotype / Licomycin resistance / Seriola quinqueradiata / Seriola dumerili / Epidemiology / Lactococus garvieae / 非凝集株 / ブリ / カンパチ / ワクチン / レンサ球菌 / ゲノム |
|---|
| Outline of Final Research Achievements |
We propose that the non-agglutinating strains belong to a new serotype II of L. garvieae as the pathogen of Seriola spp., which did not agglutinate with an antiserum against serotype I. The DNA-DNA hybridization between the both strains were higher than 70%. The 16S rRNA gene of the serotype II revealed high similarity with serotype I. The serotype II strains showed the same bacteriological characteristics as serotype I strains. The biased sinusoidal field gel electrophoretic patters of serotype II strains were similar. The result of cross-protection tests suggested the serotype I FKC might confer the insufficient protection to the fish against the serotype II, however, the immunization with the serotype II FKC was quite ineffective for the serotype I infection. To distinguish the two serotypes, a primer set was developed to target the glxR-argS intergenic region. As a result of PCR, different-sized fragments were amplified from the serotype II and serotype I strains.
|
Report
(4 results)
Research Products
(2 results)
